Bioxel Pharma Inc.
TSX VENTURE : BIP

Bioxel Pharma Inc.

May 23, 2006 08:30 ET

Bioxel Pharma Inc. Retains the Services of Maisonbrison/BarnesMcInerney, Investor Relations Specialists

SAINTE-FOY AND MONTREAL, QUEBEC--(CCNMatthews - May 23, 2006) - Bioxel Pharma Inc. (TSX VENTURE:BIP), a leading manufacturer of taxane active pharmaceutical ingredients and developer of targeted oncology drugs, is pleased to announce that it has retained the services of MaisonBrison/BarnesMcInerney to develop its investor relations. Services include the development of targeted communication strategies and support in the preparation of meetings with investors.

Pascal Delmas, President and Chief Executive Officer of Bioxel Pharma, said: "As Bioxel is embarking on another phase of its development plan, it was normal that new momentum be given to the relations Bioxel maintains with the financial community. MaisonBrison was a natural choice, because of its exceptional life sciences skills and its ability to assist us, in cooperation with BarnesMcInerney, in building ties with the financial community Canada-wide," concluded Mr. Delmas.

"We are honored that Bioxel has retained MaisonBrison/BarnesMcInerney to raise the Corporation's profile in Canada's institutional and retail financial community," indicated Jean Walter, Vice President-Life Sciences of MaisonBrison. "This choice validates the strategy we implemented last year to offer services dedicated to companies in the life sciences sector," concluded Mr. Walter.

Under the terms of the agreement of a duration of six months, subject to approval by the TSX Venture Exchange, the investor relations firm will receive monthly fees of $3,500 plus certain additional fees based on the nature of the services provided. The fees are not expected to exceed $75,000 per year. Such fees will be paid out of the general funds of the Corporation. No stock purchase options have been granted.

About Bioxel Pharma

Bioxel Pharma Inc. is an emerging leader in biopharmaceuticals, focused on developing, manufacturing and marketing taxane pharmaceutical ingredients. Taxanes are used in drug products for the treatment of cancer and other diseases, including psoriasis, rheumatoid arthritis, Alzheimer's disease and cardiovascular disease. The Corporation sells cGMP paclitaxel and develops a portfolio of other generic taxane APIs and taxane-based proprietary products for improved cancer therapy.

MaisonBrison Profile (MB)

Founded in 1983, MaisonBrison meets the communications needs of a number of Canadian public and private companies. MaisonBrison offers a wide range of services. Specializing in investor relations, public relations and media relations, MB also offers graphic design and computer graphics services and organizes marketing roadshows. The firm acts as communications department on clients' behalf or enables them to outsource certain functions of their choice.

MB's Montreal team consists of specialists in finance, communications and life sciences. The firm also has strategic alliances in Toronto and New York.

The TSX Venture Exchange has not reviewed the contents of this press release and accepts no responsibility for the adequacy or the accuracy thereof.

Contact Information

  • Bioxel Pharma Inc.
    Pascal Delmas, Pharm.D, MBA
    President and Chief Executive Office
    (418) 654-9666, ext. 230
    investisseurs@bioxelpharma.com
    or
    MaisonBrison
    Jean Walter
    Vice President-Life Sciences
    (514) 731-0000, ext. 223